Eric Silverstein1, Robin Leger, Kevin P Shea. 1. Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT 06034-4037, USA.
Abstract
BACKGROUND: While hylan G-F 20 is an approved therapy for the treatment of knee osteoarthritis, there are few reports of its use in shoulder osteoarthritis. HYPOTHESIS: Hylan G-F 20 can reduce pain and improve function in patients with glenohumeral osteoarthritis. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Thirty consecutive patients with idiopathic glenohumeral osteoarthritis who failed to respond to standard conservative measures were enrolled. Patients received 3 weekly intra-articular hylan G-F 20 injections in their affected shoulder and completed a visual analog scale for pain, the UCLA score, and the Simple Shoulder Test at baseline and at 1, 3, and 6 months after the third injection. RESULTS: Of the 30 patients, 3 withdrew during the washout period before treatment; the remaining patients (17 men and 10 women) had an average age of 62 years. The mean baseline visual analog scale score was 54, UCLA score was 15.7, and Simple Shoulder Test score was 5.7 (of 12 possible "yes" responses). At the 6-month follow-up, hylan G-F 20 significantly improved visual analog scale (mean 30, P < .001), UCLA (mean 24, P < .001), and Simple Shoulder Test (7.6 "yes" responses, P < .001) scores. More patients slept comfortably after treatment (56%) versus before treatment (15%). Nine patients had a visual analog scale improvement >40 points after 6 months. No device-related adverse events were observed. CONCLUSION: Hylan G-F 20 may have a beneficial therapeutic effect on some symptomatic patients with glenohumeral osteoarthritis.
BACKGROUND: While hylan G-F 20 is an approved therapy for the treatment of knee osteoarthritis, there are few reports of its use in shoulder osteoarthritis. HYPOTHESIS: Hylan G-F 20 can reduce pain and improve function in patients with glenohumeral osteoarthritis. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Thirty consecutive patients with idiopathic glenohumeral osteoarthritis who failed to respond to standard conservative measures were enrolled. Patients received 3 weekly intra-articular hylan G-F 20 injections in their affected shoulder and completed a visual analog scale for pain, the UCLA score, and the Simple Shoulder Test at baseline and at 1, 3, and 6 months after the third injection. RESULTS: Of the 30 patients, 3 withdrew during the washout period before treatment; the remaining patients (17 men and 10 women) had an average age of 62 years. The mean baseline visual analog scale score was 54, UCLA score was 15.7, and Simple Shoulder Test score was 5.7 (of 12 possible "yes" responses). At the 6-month follow-up, hylan G-F 20 significantly improved visual analog scale (mean 30, P < .001), UCLA (mean 24, P < .001), and Simple Shoulder Test (7.6 "yes" responses, P < .001) scores. More patients slept comfortably after treatment (56%) versus before treatment (15%). Nine patients had a visual analog scale improvement >40 points after 6 months. No device-related adverse events were observed. CONCLUSION: Hylan G-F 20 may have a beneficial therapeutic effect on some symptomatic patients with glenohumeral osteoarthritis.
Authors: Alberto Tagliafico; Giuseppe Russo; Sara Boccalini; Johan Michaud; Andrea Klauser; Giovanni Serafini; Carlo Martinoli Journal: Radiol Med Date: 2013-12-03 Impact factor: 3.469
Authors: Giuseppe Porcellini; Giovanni Merolla; Nicola Giordan; Paolo Paladini; Andrea Burini; Eugenio Cesari; Alessandro Castagna Journal: Joints Date: 2016-01-28